Journal of the Formosan Medical Association
Volume 109, Issue 7 , Pages 481-483 , July 2010

Current Status of Human Papillomavirus Vaccines

  • Barbara Ma

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    • ,
  • Richard Roden

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    • ,
  • T.-C. Wu

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    • Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    • Department of Molecular Microbiology and Immunology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    • Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    • Corresponding Author InformationCorrespondence to: Dr T.C. Wu, Department of Pathology, The Johns Hopkins School of Medicine, Cancer Research Building II, Room 309, 1550 Orleans Street, Baltimore, MD 21231, USA

References 

  1. Harper DM . Currently approved prophylactic HPV vaccines . Expert Rev Vaccines . 2009;8:1663–1679
  2. Garnett GP , Kim JJ , French K , et al.   Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes . Vaccine . 2006;24(Suppl 3):S3/178; 186
  3. Li M , Cripe TP , Estes PA , et al.   Expression of the human pa-pillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly . J Virol . 1997;71:2988–2995
  4. Fraillery D , Baud D , Pang SY , et al.   Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever . Clin Vaccine Immunol . 2007;14:1285–1295
  5. Einstein MH , Baron M , Levin MJ , et al.   Comparison of the immunogenicity and safety of Cervarix(tm) and Gardasil(r) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years . Hum Vaccin . 2009;5:705–719
  6. Merck & Co., Inc.  . Whitehouse Station, NJ, USA . Available at www.merck.com [Date accessed: February 24, 2010]
  7. Jagu S , Karanam B , Gambhira R , et al.   Concatenated multitype L2 fusion proteins as candidate prophylactic panhuman papillomavirus vaccines . J Natl Cancer Inst . 2009;101:782–792
  8. Lin K , Doolan K , Hung CF , et al.   Perspectives for preventive and therapeutic HPV vaccines . J Formos Med Assoc . 2010;109:4–24
  9. Kenter GG , Welters MJ , Valentijn AR , et al.   Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia . N Engl J Med . 2009;361:1838–1847
  10. Eisai  . A Study of Amolimogene (ZYC101a) in Patients with High Grade Cervical Intraepithelial Lesions of the Uterine Cervix . Available at http://clinicaltrials.gov/ct2/show/NCT00264732
  11. NCI  . Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia . Available at: http://clinicaltrials.gov/ct2/show/NCT00788164

PII: S0929-6646(10)60081-2

doi: 10.1016/S0929-6646(10)60081-2

Journal of the Formosan Medical Association
Volume 109, Issue 7 , Pages 481-483 , July 2010

Article Tools